Skip to main content
SpringerLink
Log in

Ocular manifestations of autoimmune bullous disease have the potential for sight-threatening complications, but are often difficult to treat

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Laforest C, Huilgo SC, Casson R, et al. Autoimmune bullous diseases: ocular manifestations and management. Drugs 2005; 65(13): 1767–79

    Article  PubMed  Google Scholar 

  2. Camisa C, Meisler DM. Immunobullous diseases with ocular involvement. Dermatol Clin 1992; 10: 555–70

    PubMed  CAS  Google Scholar 

  3. Baer JC, Hemady RK. Ocular manifestations of systemic immune disease. In: Bosniak S, editor. Principles and practice of ophthalmic plastic and reconstructive surgery. Vol. 1. Philadelphia (PA): WB Saunders Company, 1996: 94–119

    Google Scholar 

  4. Korman NJ. New immunomodulating drugs in autoimmune blistering disease. Dermatol Clin 2001; 19: 637–48

    Article  PubMed  CAS  Google Scholar 

  5. Mondino BJ. Cicatricial pemphigoid and erythema multiforme. Ophthalmology 1990; 97: 939–52

    PubMed  CAS  Google Scholar 

  6. Huilgol SC, Black MM. Management of the immunobullous disorders: 1. Pemphigoid. Clin Exp Dermatol 1995; 20: 189–201

    Article  PubMed  CAS  Google Scholar 

  7. Bernauer W, Broadway DC, Wright P. Chronic progressive conjunctival cicatrisation. Eye 1993; 7: 371–8

    Article  PubMed  Google Scholar 

  8. Ahmed AR, Hombal SM. Cicatricial pemphigoid. Int J Dermatol 1986; 25: 90–6

    Article  PubMed  CAS  Google Scholar 

  9. Leonard JN, Wright P, Williams DM, et al. The relationship between linear IgA disease and benign mucous membrane pemphigoid. Br J Dermatol 1984; 110: 307–14

    Article  PubMed  CAS  Google Scholar 

  10. Yeh SW, Ahmed B, Sami N, et al. Blistering disorders: diagnosis and treatment. Dermatol Ther 2003; 16: 214–23

    Article  PubMed  CAS  Google Scholar 

  11. Wojnarowska F, Frith P. Linear IgA disease. Dev Ophthalmol 1997; 28: 64–72

    Article  PubMed  CAS  Google Scholar 

  12. Daoud YJ, Cervantes R, Foster S, et al. Ocular pemphigus. J Am Acad Dermatol 2005 Oct; 53: 585–90

    Article  PubMed  Google Scholar 

  13. Kirtschig G, Murrell D, Wojnarowska F, et al. Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch Dermatol 2002; 138: 380–4

    Article  PubMed  Google Scholar 

  14. Fleming JC, Cape RC. Surgical intervention in conjunction with medical treatment of cicaticial pemphigoid. In: Bosniak S, editor. Principles and practice of ophthalmic plastic and reconstructive surgery. Vol. 1. Philadelphia (PA): WB Saunders Company, 1996: 196–202

    Google Scholar 

  15. Foster CS, Wilson LA, Ekins MB. Immunosuppressive therapy for progressive cicatricial pemphigoid. Ophthalmology 1982; 89: 340–53

    PubMed  CAS  Google Scholar 

  16. McCluskey P, Chang JH, Singh R, et al. Methotrexate therapy for ocular cicatricial pemphigoid. Ophthalmology 2004; 111: 796–801

    Article  PubMed  Google Scholar 

  17. Ahmed M, Ghassan Z, Khawaja F, et al. Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment. Prog Retin Eye Res 2004; 23: 579–92

    Article  PubMed  Google Scholar 

  18. Huilgol SC, Black MM. Management of the immunobullous disorders II Pemphigus. Clin Exp Dermatol 1995; 20: 283–93

    Article  PubMed  CAS  Google Scholar 

  19. Donnenfeld ED, Perry HD, Wallerstein A, et al. Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid. Opthalmology 1999; 106: 72–8

    Article  CAS  Google Scholar 

  20. Secchi AAG, Tognon MS. Intraoperative mitomycin C in the treatment of cicatricial obliterations of conjunctival fornices. Am J Ophthamol 1996; 122: 728–30

    CAS  Google Scholar 

  21. Celis J, Lopez N, Garcia M, et al. Subconjunctival mitomycin for the treatment of ocular cicatricial pemphigoid. Arch Soc Esp Oftalmol 2002; 77: 501–6

    Google Scholar 

  22. Hall VC, Liesegang TJ, Kostick DA, et al. Ocular mucous membrane pemphigoid and ocular pemphigus vulgaris treated topically with tacrolimus ointment. Arch Dermatol 2003; 139: 1083–4

    Article  PubMed  Google Scholar 

  23. Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2004; 111: 45–52

    Article  Google Scholar 

  24. Hoohwy T, Bang K, Steiniche T, et al. Alemtuzumab-induced remission of both severe paraneoplastic pemphigus and lymphocytic leukaemia. Eur J Haematol 2004; 73: 206–9

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ocular manifestations of autoimmune bullous disease have the potential for sight-threatening complications, but are often difficult to treat. Drugs Ther. Perspect 22, 16–19 (2006). https://doi.org/10.2165/00042310-200622090-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200622090-00005

Search

Navigation